25% of Patients Achieve Endoscopic Remission in Phase 2a EMERALD-1 Trial for MORF-057
Data from the phase 2a trial showed 25.7% of patients with UC demonstrated endoscopic improvement and 45.7% achieved clinical response after week 12.
United States Pbruce Sands Praveen Tipirneni Henryd Janowitz Alimentiv Bruce Sands Mount Sinai Health System
Source: hcplive.com